Multiple Myeloma, Multiple Sclerosis, Breast Cancer Drugs Are Among Those Going Off Patent in 2020

AIS Health asked various industry experts about what specialty drugs are expected to see patent expiration — and potentially generic or biosimilar competition — in 2020. Here’s what Martin Burruano, R.Ph., vice president, pharmacy services at Independent Health; April M. Kunze, Pharm.D., senior director, clinical formulary development and trend management strategy at Prime Therapeutics LLC; and Mesfin Tegenu, R.Ph., president of PerformRx, LLC, told us:

Eligard (leuprolide acetate): prostate cancer,

Forteo (teriparatide): osteoporosis,

Juxtapid (lomitapide): familial hypercholesterolemia,

Korlym (mifepristone): endocrine gland diseases,

Lucentis (ranibizumab): macular degeneration,

Pomalyst (pomalidomide): multiple myeloma,

Sprycel (dasatinib): acute lymphoblastic leukemia and chronic myeloid leukemia,

Tecfidera (dimethyl fumarate): multiple sclerosis (MS),

Thalomid (thalidomide): multiple myeloma and leprosy,

Truvada (emtricitabine/tenofovir disoproxil fumarate): HIV-1 infection and HIV pre-exposure prophylaxis (PrEP),

Tykerb (lapatinib): breast cancer, and

Tysabri (natalizumab): MS.

Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
September 8

New FDA Approvals: FDA Converts Accelerated Approval to Full for Tabrecta

READ MORE
scales-of-justice
September 8

Johnson & Johnson Files Lawsuit Against Copay Maximizer Company SaveOnSP

READ MORE
pills-in-a-dollar-shape
September 8

Copay Maximizer Programs Are Coming Under Fire

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today